Robin Gelburd, JD, details the dip in telehealth claims observed during April 2021.
In April 2021, telehealth utilization fell nationally for the third straight month, according to FAIR Health’s Monthly Telehealth Regional Tracker. Telehealth claim lines declined 12.5 percent nationally as a percentage of medical claim lines, decreasing from 5.6 percent of claim lines in March 2021 to 4.9 percent in April (Exhibit 1). This was a greater decrease than the drop of 5.1 percent in March but not as great as the decrease of 15.7 percent in February. Telehealth usage also declined in April in all four US census regions, with the greatest decline in the South, where the decrease was 12.2 percent. The data represent the privately insured population, excluding Medicare and Medicaid.
Exhibit 1. Monthly Telehealth Regional Tracker, March versus April 2021, United States
Click to enlarge. (Source: FAIR Health)
The decline in telehealth utilization appears largely to be driven by the return of non-mental-health services from telehealth—where they had shifted during the COVID-19 pandemic—to in-person settings. The percentage of telehealth claim lines associated with mental health conditions, the number one telehealth diagnosis, continued to rise nationally and in every region. Nationally, for example, mental health conditions increased from 57 percent of telehealth claim lines in March 2021 to 58.6 percent in April. Likewise in April, psychotherapeutic/psychiatric codes increased nationally as a percentage of telehealth procedure codes, whereas evaluation and management (E&M) codes decreased. Within the category of mental health conditions, there were no changes in the rankings of top mental health diagnoses nationally or regionally.
In April, acute respiratory diseases and infections increased as a percentage of telehealth claim lines nationally and in the Midwest and South. As the COVID-19 pandemic wanes, this suggests a return to non-COVID respiratory conditions, such as colds and bronchitis. Also in April, general signs and symptoms joined the top five telehealth diagnoses in the West, again suggesting a return to more “ordinary,” non-COVID conditions such as colds and stomach viruses (Exhibit 2).
Click to enlarge. (Source: FAIR Health)
About the Monthly Telehealth Regional Tracker
Launched in May 2020 as a free service, the Monthly Telehealth Regional Tracker uses FAIR Health data to track how telehealth is evolving from month to month. An interactive map of the four US census regions allows the user to view an infographic on telehealth in a specific month in the nation as a whole or in individual regions. Each infographic shows month-to-month changes in volume of telehealth claim lines, top five telehealth procedure codes, top five telehealth diagnoses (or diagnostic categories) and top five granular diagnoses within the most common diagnostic category.
FAIR Health’s Monthly Telehealth Regional Tracker continues to reveal changes in the evolution of telehealth as the COVID-19 pandemic recedes. This is one of many ways we pursue our healthcare transparency mission.
For the Monthly Telehealth Regional Tracker, click here.
Author Information
Robin Gelburd, JD, is the President of FAIR Health, a national, independent nonprofit organization with the mission of bringing transparency to healthcare costs and health insurance information. FAIR Health possesses the nation’s largest collection of private healthcare claims data, which includes over 34 billion claim records and is growing at a rate of over 2 billion claim records a year. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D; FAIR Health includes among the private claims data in its database, data on Medicare Advantage enrollees. Gelburd is a nationally recognized expert on healthcare policy, data and transparency.
Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA
August 15th 2025Children with spinal muscular atrophy (SMA) showed motor function improvements after switching to onasemnogene abeparvovec following prior treatment with nusinersen or risdiplam in a real-world study.
Read More
PCPs Have Unique Opportunity to Detect, Manage CKD
August 14th 2025As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC
July 31st 2025Taletrectinib was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a preferred option for the first-line and subsequent treatment of advanced ROS1-positive non–small cell lung cancer (NSCLC).
Read More